October 7, 2025
ME&MGopen™ digital biomarkers help track generalized myasthenia gravis symptoms.
At the WMS congress in Vienna, Austria, in October 2025, we presented our ME&MGopen™ app, developed to better understand generalized myasthenia gravis (gMG).
By measuring digital biomarkers and administering standard clinical questionnaires at home, the app makes it possible to assess how symptoms manifest under real-life conditions.
In Chicago, April 18-22, 2026, Ad Scientiam presented 4 scientific posters at the American Academy of Neurology, covering MSCopilot® in MS and ME&MG™ in generalized autoimmune myasthenia.
April 18, 2026
At the Cystic Fibrosis Scientific Days 2025, we presented MuCopilot®, our home monitoring tool based on digital biomarkers measured via smartphone.
March 9, 2026
In Dubai in December 2025, we presented MS-DETECT data on the correlation between MSCopilot® digital biomarkers and traditional clinical assessments.
December 5, 2025
Talk to our experts and discover how our solutions integrate into your practice or studies.
This site uses analytics cookies
We use Countly to measure audience and improve your experience. This data remains anonymous and is not shared with third parties.